Financial results - NOBLESSE PHARMA SRL

Financial Summary - Noblesse Pharma Srl
Unique identification code: 24923780
Registration number: J40/133/2009
Nace: 4646
Sales - Ron
50.361
Net Profit - Ron
4.382
Employees
1
Open Account
Company Noblesse Pharma Srl with Fiscal Code 24923780 recorded a turnover of 2024 of 50.361, with a net profit of 4.382 and having an average number of employees of 1. The company operates in the field of Comerţ cu ridicata al produselor farmaceutice și medicale having the NACE code 4646.
Sales - Ron

Sales, Profit, Employees, Total Income, Financial Results - Noblesse Pharma Srl

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Sales - EUR 32.936 49.083 50.313 54.992 44.217 50.673 56.807 52.636 50.489 50.361
Total Income - EUR 31.070 49.601 50.256 57.117 44.281 51.577 58.794 50.796 51.021 51.928
Total Expenses - EUR 23.335 37.102 45.867 57.436 40.268 44.320 51.104 42.674 45.670 47.326
Gross Profit/Loss - EUR 7.736 12.499 4.389 -319 4.013 7.257 7.690 8.122 5.350 4.601
Net Profit/Loss - EUR 6.734 10.844 2.571 -931 3.553 6.783 7.219 7.709 4.895 4.382
Employees 1 1 1 1 1 1 1 1 1 1
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded. In the last year of activity, the sales increased by 0.3%, from 50.489 euro in the year 2023, to 50.361 euro in 2024. The Net Profit decreased by -486 euro, from 4.895 euro in 2023, to 4.382 in the last year.
Sales - Ron
Net Profit - Ron
Employees

Check the financial reports for the company - Noblesse Pharma Srl

Rating financiar

Financial Rating -
NOBLESSE PHARMA SRL

See the company's note based on the submitted financial data, relative to the industry of which it is a part.

Financial Rating
Limite de plata

Payment Limits -
Noblesse Pharma Srl

See the company's payment capacity for situations in which you conclude contracts with payment terms.

Check Payment Limits
Probabilitate de insolventa

Prob. of insolvency -
Noblesse Pharma Srl

It determines the risk of insolvency based on the submitted accounting balance.

Insolvency Probability
Rapoarte financiare

Financial Reports -
Noblesse Pharma Srl

Check all the financial reports of the company and know the risks in collaboration with it.

Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.

Debts, Equity, Inventories, Receivables, Accounts, Assets - Noblesse Pharma Srl - CUI 24923780

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Fixed Assets 2.115 1.334 28.301 26.477 53.510 50.420 44.803 38.205 31.738 22.618
Current Assets 21.910 27.503 30.432 34.759 22.094 24.915 24.060 30.753 38.462 49.843
Inventories 10.068 8.997 8.819 7.466 7.564 9.605 11.869 10.974 10.349 20.858
Receivables 11.638 13.628 20.977 23.466 5.416 3.508 1.723 1.320 2.172 1.961
Cash 204 4.878 635 3.827 9.114 11.801 10.468 18.458 25.941 27.024
Shareholders Funds 8.524 19.282 21.526 20.200 53.635 64.265 64.602 67.165 68.934 71.292
Social Capital 12.886 12.755 12.539 12.309 12.071 11.842 11.579 11.615 11.580 11.515
Debts 15.640 9.827 37.467 41.170 22.148 11.214 4.790 2.833 2.125 1.553
Income in Advance 0 0 0 0 0 0 0 0 0 0
Exchange rate - RON 4.9743 4.9465 4.9315 4.9468 4.8371 4.7454 4.6535 4.5681 4.4908 4.445
Main CAEN "4646 - 4646"
CAEN Financial Year 4646
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of 49.843 euro in 2024 which includes Inventories of 20.858 euro, Receivables of 1.961 euro and cash availability of 27.024 euro.
The company's Equity was valued at 71.292 euro, while total Liabilities amounted to 1.553 euro. Equity increased by 2.743 euro, from 68.934 euro in 2023, to 71.292 in 2024.

Risk Reports Prices

Reviews - Noblesse Pharma Srl

Comments - Noblesse Pharma Srl

Similar services useful for checking companies and business development.

SellNet

Get the contact details for any company and get in touch with it.

Sectoral Studies

Knows the market and develops its own development strategies according to sectorial data.

Databases

Export in excel files the data of the companies selected according to the desired criteria.

Import - Export

Find importers and exporters according to the type of activity and the countries in which they carry it out.

Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.